Suven Life Scie. (SUVEN)

FairStock Score: 9/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding is high at 67.36%, aligning management with shareholders.
• Reported sales growth of 74.53%, though from a very small base of ₹3 crore in the latest quarter.
• Book value remains positive at ₹35.75 per share, and debt/equity is reported as N/A, suggesting no meaningful debt burden.
• The stock is trading 44% below its 52-week high of ₹371, reflecting some de-risking of expectations.

Concerns

• Latest quarter revenue of ₹3 crore is dwarfed by a net loss of ₹102 crore, indicating severe cash burn.
• Negative ROE of -7.11% and ROCE of -86.96% show significant destruction of shareholder capital.
• At P/B of 5.81, the market is paying nearly six times book value for a loss-making enterprise.
• Piotroski F-Score of 3/9 signals weak financial health, and there is no dividend yield to compensate.

AI Analysis

Dear investor, when I look at Suven Life Scie., the first thing I notice is that I cannot determine earnings power, because there are none. The latest quarter tells the tale: revenue of ₹3 crore and a net loss of ₹102 crore. That is not a business; that is a laboratory consuming capital while waiting for a miracle. A P/E of zero is meaningless; the more relevant figures are P/B of 5.81 against book value of ₹35.75, and return on equity of -7.11%. Worse, ROCE is -86.96%, meaning every rupee employed in this business is largely being burned. Sales growth of 74.53% looks exciting, but from a base of ₹3 crore per quarter, it is a rounding error. Even Benjamin Graham would say: pay attention to the loss column. Buffett would ask: Is there a durable competitive advantage? I see no moat here, only research spending and high promoter holding of 67.36%, which is positive but not enough. The stock has fallen from ₹371 to ₹207.66, but that does not make it cheap. A Piotroski F-Score of 3/9 and FairStock Score of 9/100 reinforce my caution. There is no dividend to reward patient capital. This could be a turnaround story if new drug approvals or licensing deals materialise, but for a value investor, hope is not a strategy. I would need to see revenue scaling up dramatically, losses narrowing, and return on capital moving toward positive territory. Until then, this belongs in the too-hard pile. Price is what you pay; value is what you get—and here, value is difficult to identify. I will watch from the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer